Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function
An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study of the Pharmacokinetics, Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients With Advanced Solid Tumours and Normal Renal Function or Renal Impairment
Sponsor: AstraZeneca
Listed as NCT01894256, this PHASE1 trial focuses on Solid Tumours and remains completed. Sponsored by AstraZeneca, it has been updated 8 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands , Bordeaux, France , Brussels (Jette), Belgium , Dijon, France , Edegem, Belgium , Herlev, Denmark , København Ø, Denmark , Leuven, Belgium , Liège, Belgium , Maastricht, Netherlands and 3 more locations